Methylphenidate in pregnancy: A multicenter, prospective, comparative, observational study

Journal of Clinical Psychiatry

Volumn 77, Issue 9, 2016, Pages 1176-1181

  Diav Citrin, Orna ^a,b   Shechtman, Svetlana ^a   Arnon, Judy ^a   Wajnberg, Rebecka ^a   Borisch, Cornelia ^c   Beck, Evelin ^c   Richardson, Jonathan Luke ^d   Bozzo, Pina ^e   Nulman, Irena ^e   Ornoy, Asher ^a,b  

^a MINISTRY OF HEALTH   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy   (Germany)

^d UK Teratology Information Service   (United Kingdom)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ADULT; COMPARATIVE STUDY; CONFERENCE PAPER; CONGENITAL DEAFNESS; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; ENCEPHALOCELE; ENVIRONMENTAL EXPOSURE; FEMALE; GESTATIONAL AGE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPOSPADIAS; MAJOR CLINICAL STUDY; MATERNAL AGE; MULTICENTER STUDY; MUSCLE HYPOTONIA; OBSERVATIONAL STUDY; ORGANOGENESIS; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPONTANEOUS ABORTION; TERATOGENESIS; TRACHEA STENOSIS; TRISOMY 21; ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; CARDIOVASCULAR ABNORMALITIES; CHEMICALLY INDUCED; CLINICAL TRIAL; FOLLOW UP; INDUCED ABORTION; PREGNANCY COMPLICATIONS; RISK; STATISTICS AND NUMERICAL DATA;

ABNORMALITIES, DRUG-INDUCED; ABORTION, INDUCED; ABORTION, SPONTANEOUS; CARDIOVASCULAR ABNORMALITIES; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; METHYLPHENIDATE; PREGNANCY; PREGNANCY COMPLICATIONS; RISK;

EID: 84989300031     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15m10083     Document Type: Conference Paper

References (22)

1. Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): A public health view. Ment Retard Dev Disabil Res Rev. 2002;8(3):162-170. doi:10.102/mrd.1036 PubMed.
2. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948. doi:10.176/ajp.207.164.6.942 PubMed.
3. Bagot KS, Kaminer Y. Efficacy of stimulants for cognitive enhancement in non-Attention deficit hyperactivity disorder youth: A systematic review. Addiction. 2014;109(4):547-557. doi:10.1/ad.12460 PubMed.
4. Haervig KB, Mortensen LH, Hansen AV, et al. Use of ADHD medication during pregnancy from 1999 to 2010: A Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23(5):526-533. doi:10.102/pds.360 PubMed.
5. Shah NS, Yates JD. Placental transfer and tissue distribution of dextro-Amphetamine in the mouse. Arch Int Pharmacodyn Ther. 1978;233(2):200-208. PubMed.
6. Burchfield DJ, Lucas VW, Abrams RM, et al. Disposition and pharmacodynamics of methamphetamine in pregnant sheep. JAMA. 1991;265(15):1968-1973. doi:10.101/jama.191.0346015072026 PubMed.
7. Teo SK, Stirling DI, Thomas SD, et al. The perinatal and postnatal toxicity of d-methylphenidate and d, l-methylphenidate in rats. Reprod Toxicol. 2002;16(4):353-366. doi:10.1016/S0890-6238(02)04-8 PubMed.
8. Teo SK, Stirling DI, Hoberman AM, et al. d-Methylphenidate and d, l-methylphenidate are not developmental toxicants in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2003;68(2):162-171. doi:10.102/bdrb.1018 PubMed.
9. Beckman DA, Schneider M, Youreneff M, et al. Developmental toxicity assessment of d, lmethylphenidate and d-methylphenidate in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2008;83(5):489-501. PubMed.
10. Bolea-Alamanac BM, Green A, Verma G, et al. Methylphenidate use in pregnancy and lactation: A systematic review of evidence. Br J Clin Pharmacol. 2014;77(1):96-101. doi:10.1/bcp.12138 PubMed.
11. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group; 1977:346-347.
12. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A reference guide to Fetal and Neonatal Risk. 9th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2011:942-943.
13. Debooy VD, Seshia MM, Tenenbein M, et al. Intravenous pentazocine and methylphenidate abuse during pregnancy: maternal lifestyle and infant outcome. Am J Dis Child. 1993;147(10):1062-1065. doi:10.101/archpedi.193.0216034048012 PubMed.
14. Dideriksen D, Pottegard A, Hallas J, et al. First trimester in utero exposure to methylphenidate. Basic Clin Pharmacol Toxicol. 2013;112(2):73-76. doi:10.1/bcpt.12034 PubMed.
15. Kallen B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel). 2013;6(10):1221-1286. doi:10.390/ph610121 PubMed.
16. Pottegard A, Hallas J, Andersen JT, et al. Firsttrimester exposure to methylphenidate: A population-based cohort study. J Clin Psychiatry. 2014;75(1):e88-e93. doi:10.408/JCP.13m08708 PubMed.
17. McFadyen-Leussis MP, Lewis SP, Bond TL, et al. Prenatal exposure to methylphenidate hydrochloride decreases anxiety and increases exploration in mice. Pharmacol Biochem Behav. 2004;77(3):491-500. doi:10.1016/j.pb.203.12.01 PubMed.
18. Lloyd SA, Oltean C, Pass H, et al. Prenatal exposure to psychostimulants increases impulsivity, compulsivity, and motivation for rewards in adult mice. Physiol Behav. 2013;119:43-51. doi:10.1016/j.physbeh.2013.05.038 PubMed.
19. Lepelletier FX, Tauber C, Nicolas C, et al. Prenatal exposure to methylphenidate affects the dopamine system and the reactivity to natural reward in adulthood in rats. Int J Neuropsychopharmacol. 2015;18(4):pyu044. doi:10.1093/ijnp/pyu04 PubMed.
20. Rasmussen SA, Olney RS, Holmes LB, et al; National Birth Defects Prevention Study. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2003;67(3):193-201. doi:10.102/bdra.1012PubMed.
21. Merks JH, van Karnebeek CD, Caron HN, et al. Phenotypic abnormalities: Terminology and classification. Am J Med Genet A. 2003;123A(3):211-230. doi:10.102/ajmg.a.20249PubMed.
22. Bro SP, Kjaersgaard MI, Parner ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139-147. doi:10.2147/CLEP.S72906 PubMed.